Will novel oral formulations change the management of inflammatory bowel disease?

References

• Atreya R, Neurath MF. IBD pathogenesis in 2014: molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol. 2015;12(2):67–68.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4(3):160–170.
   PubMedGoogle Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–599.
   PubMed Web of Science ®Google Scholar
• Coskun M, Steenholdt C, de Boer NK, et al. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease. Clin Pharmacokinet. 2016;55(3):257–274.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369(8):754–762.
   PubMed Web of Science ®Google Scholar
• Chandar AK, Singh S, Murad MH, et al. Efficacy and safety of natalizumab and vedolizumab for the management of Crohn’s disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(7):1695–1708.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537–545.
   PubMed Web of Science ®Google Scholar
• Olesen CM, Coskun M, Peyrin-Biroulet L, et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016;159:110–119.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60(8):1068–1075.
   PubMed Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–318.
   PubMed Web of Science ®Google Scholar
• Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879–2885.
   PubMed Web of Science ®Google Scholar
• Amiot A, Grimaud J-C, Treton X, et al. The French real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicenter cohort study. In. United European Gastroenterology Week. OP049, Vienna. October 15–19, 2015.
   Google Scholar
• Amiot A, Peyrin-Biroulet L, Stefanescu C, et al. Management of IBD after anti-TNF failure. In: United European Gastroenterology Week, OP054, Vienna, October 15–19, 2015
   Google Scholar
• Baumgart D, Atreya R, Bachmann O, et al. Vedolizumab for inflammatory bowel disease in clinical practice - experience from a prospective German registry. In: United European Gastroenterology Week, OP053, Vienna, October 15–19, 2015
   Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Nikfar S, Abdollahi M. Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin Investig Drugs. 2015;24(7):949–956.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287.
   PubMed Web of Science ®Google Scholar
• Coskun M, Salem M, Pedersen J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76(10):1–8.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243.
   PubMed Web of Science ®Google Scholar
• Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513–526.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485–1493.
   PubMed Web of Science ®Google Scholar
• Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(3):603–617.
   PubMed Web of Science ®Google Scholar
• A Study Evaluating the Efficacy and Safety of CP-690,550 in Patients with Moderate to Severe Ulcerative Colitis [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01465763.
   Google Scholar
• A Study to Evaluate Both the Efficacy and Safety Profile of CP-690,550 in Patients with Moderately to Severely Active Ulcerative Colitis (OCTAVE) [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01458951.
   Google Scholar
• A Study of Oral CP-690,550 as a Maintenance Therapy for Ulcerative Colitis (OCTAVE) [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01458574.
   Google Scholar
• Long-Term Study of CP-690,550 in Subjects with Ulcerative Colitis (OCTAVE) [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01470612.
   Google Scholar
• Panes J, Su C, Bushmakin AG, et al. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol. 2015;15:14.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–2829.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Danese S. Tofacitinib: janus bifrons in ulcerative colitis treatment. Gastroenterology. 2013;144(5):1136–1138.
   PubMedGoogle Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–874.
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of GLPG0634 in Subjects with Active Crohn’s Disease [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02048618.
   Google Scholar
• A Study of Safety and Effectiveness of JNJ-54781532 in Patients with Moderately to Severely Active Ulcerative Colitis [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01959282.
   Google Scholar
• Wegner C, Stadelmann C, Pfortner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227(1–2):133–143.
   PubMed Web of Science ®Google Scholar
• Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004;156(1–2):3–9.
   PubMed Web of Science ®Google Scholar
• Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014;262:A66–71.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Colombel JF, et al. A phase II study of laquinimod in Crohn’s disease. Gut. 2015;64(8):1227–1235.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kageyama S, Andou A, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013;7(11):e533–e542.
   PubMedGoogle Scholar
• Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149(7):1775–1783.
   PubMed Web of Science ®Google Scholar
• Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348(1):68–72.
   PubMed Web of Science ®Google Scholar
• Rosen H, Gonzalez-Cabrera PJ, Sanna MG, et al. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem. 2009;78:743–768.
   PubMed Web of Science ®Google Scholar
• Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem. 2004;92(5):913–922.
   PubMed Web of Science ®Google Scholar
• Degagne E, Saba JD. S1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin Exp Gastroenterol. 2014;7:205–214.
   PubMedGoogle Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. The Touchstone study: a randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe ulcerative colitis. Gastroenterology. 2015;148:S–93.
   Web of Science ®Google Scholar
• Open-label extension of RPC1063 as therapy for moderate to severe ulcerative colitis [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02531126?term=RPC1063&rank=7.
   Google Scholar
• Safety and efficacy trial of RPC1063 for moderate to severe ulcerative colitis [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02435992?term=RPC1063&rank=5.
   Google Scholar
• Efficacy and safety trial of RCP1063 for moderate to severe Crohn’s disease [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02531113?term=RPC1063&rank=6.
   Google Scholar
• Safety and efficacy of APD334 in patients with ulcerative colitis [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02447302?term=APD334&rank=1.
   Google Scholar
• Safety and efficacy of MT-1303 in subjects with moderate to severe active Crohn’s disease [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02378688?term=MT-1303&rank=10.
   Google Scholar
• Extension study of MT-1303 in subjects with Crohn’s disease [cited 2016 March 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02389790?term=MT-1303&rank=11
   Google Scholar
• Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002;2(1):46–53.
   PubMed Web of Science ®Google Scholar
• Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137–161.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Miyazono K. Ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390(6659):465–471.
   PubMed Web of Science ®Google Scholar
• Kulkarni AB, Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol. 1993;143(1):3–9.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med. 1996;183(6):2605–2616.
   PubMed Web of Science ®Google Scholar
• Powrie F, Carlino J, Leach MW, et al. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med. 1996;183(6):2669–2674.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Caruso R, Pallone F. Role of Smad7 in inflammatory bowel diseases. World J Gastroenterol. 2012;18(40):5664–5668.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108(4):601–609.
   PubMed Web of Science ®Google Scholar
• Marafini I, Zorzi F, Codazza S, et al. TGF-Beta signaling manipulation as potential therapy for IBD. Curr Drug Targets. 2013;14(12):1400–1404.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol Ther. 2012;20(4):870–876.
   PubMed Web of Science ®Google Scholar
• Boirivant M, Pallone F, Di GC, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006;131(6):1786–1798.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372(12):1104–1113.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety study of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease [cited 2016 March 1]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02596893?term=NCT02596893&rank=1
   Google Scholar
• An efficacy and safety study of mongersen (GED-0301) in subjects with active ulcerative colitis [cited 2016 March 1]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02601300?term=NCT02601300&rank=1.
   Google Scholar
• Burke JP, Mulsow JJ, O’Keane C, et al. Fibrogenesis in Crohn’s disease. Am J Gastroenterol. 2007;102(2):439–448.
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7(1):16–26.
   PubMed Web of Science ®Google Scholar
• Nijhuis A, Biancheri P, Lewis A, et al. In Crohn’s disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. Clin Sci (Lond). 2014;127(5):341–350.
   PubMed Web of Science ®Google Scholar
• Mulsow JJ, Watson RW, Fitzpatrick JM, et al. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg. 2005;242(6):880–889.
   PubMed Web of Science ®Google Scholar
• Regan MC, Flavin BM, Fitzpatrick JM, et al. Stricture formation in Crohn’s disease: the role of intestinal fibroblasts. Ann Surg. 2000;231(1):46–50.
   PubMed Web of Science ®Google Scholar
• Li C, Flynn RS, Grider JR, et al. Increased activation of latent TGF-beta1 by alphaVbeta3 in human Crohn’s disease and fibrosis in TNBS colitis can be prevented by cilengitide. Inflamm Bowel Dis. 2013;19(13):2829–2839.
   PubMed Web of Science ®Google Scholar
• Li C, Iness A, Yoon J, et al. Noncanonical STAT3 activation regulates excess TGF-beta1 and collagen I expression in muscle of stricturing Crohn’s disease. J Immunol. 2015;194(7):3422–3431.
   PubMed Web of Science ®Google Scholar
• Feagins LA. Role of transforming growth factor-beta in inflammatory bowel disease and colitis-associated colon cancer. Inflamm Bowel Dis. 2010;16(11):1963–1968.
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99–106.
   PubMed Web of Science ®Google Scholar
• Medina C, Santos-Martinez MJ, Santana A, et al. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. J Pathol. 2011;224(4):461–472.
   PubMed Web of Science ®Google Scholar
• Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372(13):1189–1191.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Scharl M, Frei S, Pesch T, et al. Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut. 2013;62(1):63–72.
   PubMed Web of Science ®Google Scholar
• Bataille F, Rohrmeier C, Bates R, et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn’s disease. Inflamm Bowel Dis. 2008;14(11):1514–1527.
   PubMed Web of Science ®Google Scholar
• Frei SM, Hemsley C, Pesch T, et al. The role for dickkopf-homolog-1 in the pathogenesis of Crohn’s disease-associated fistulae. PLoS One. 2013;8(11):e78882.
   PubMed Web of Science ®Google Scholar
• Bates RC, Bellovin DI, Brown C, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005;115(2):339–347.
   PubMed Web of Science ®Google Scholar
• Uttamsingh S, Bao X, Nguyen KT, et al. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene. 2008;27(18):2626–2634.
   PubMed Web of Science ®Google Scholar
• Bates RC, Mercurio AM. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell. 2003;14(5):1790–1800.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Fairchild AO, Gilroy E, et al. Inflammatory bowel disease patients’ willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol. 2015;110(12):1675–1681.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–279.
   PubMed Web of Science ®Google Scholar